PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34298684-0	2021	The BET Inhibitor JQ1 Augments the Antitumor Efficacy of Gemcitabine in Preclinical Models of Pancreatic Cancer.	gemcitabine	57-68	delta/notch like EGF repeat containing	Homo sapiens	4-7	
34298684-5	2021	BET inhibitors (JQ1 or I-BET762) + gemcitabine were synergistic in vitro, in Panc1, MiaPaCa2 and Su86 PC cell lines.	gemcitabine	35-46	delta/notch like EGF repeat containing	Homo sapiens	0-3	
34298684-8	2021	Notably, RNA-seq data showed that JQ1 + gemcitabine selectively inhibited HMGCS2 and APOC1 ~6-fold, compared to controls.	gemcitabine	40-51	3-hydroxy-3-methylglutaryl-CoA synthase 2	Homo sapiens	74-80	
34298684-8	2021	Notably, RNA-seq data showed that JQ1 + gemcitabine selectively inhibited HMGCS2 and APOC1 ~6-fold, compared to controls.	gemcitabine	40-51	apolipoprotein C1	Homo sapiens	85-90	
34298684-10	2021	IPA data indicated that JQ1 + gemcitabine selectively inhibited the LXR/RXR activation pathway, suggesting the hypothesis that this inhibition may contribute to the observed in vivo efficacy of JQ1 + gemcitabine.	gemcitabine	30-41	retinoid X receptor alpha	Homo sapiens	72-75	
34298684-10	2021	IPA data indicated that JQ1 + gemcitabine selectively inhibited the LXR/RXR activation pathway, suggesting the hypothesis that this inhibition may contribute to the observed in vivo efficacy of JQ1 + gemcitabine.	gemcitabine	200-211	retinoid X receptor alpha	Homo sapiens	72-75